Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Cell-free regenerative medicine: identifying the best source of mesenchymal stem cells for skin therapy in Systemic Sclerosis.

Napolitano F., Giudice V., D'Esposito V., Prevete N., Scala P., de Paulis A.

Prospective Study on Chronic Wound, Immune Modulation, Autoimmune Research, published in Front Cell Dev Biol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Cell Dev Biol (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
40046231
PMCID
PMC11880212
DOI
10.3389/fcell.2025.1518412
Citations
3

Abstract (original English)

Introduction Systemic Sclerosis (SSc) is a rare chronic systemic autoimmune disease characterized by fibrosis of the skin and internal organs and vasculopathy. Raynaud's phenomenon is typically the earliest clinical manifestation accompanied by skin inflammation, finger ulcers, and organ manifestations, including pulmonary fibrosis. There is an urgent need for the development of effective targeted therapeutic intervention for SSc patients. A greater focus has been placed on bioactive factors secreted by Mesenchymal Stem Cells (MSCs), with immunomodulatory and regenerative potentials. Current data report a different secretion profile of MSCs, depending on the tissue of origin. Understanding of the secretion profile of different MSCs is necessary to identify the most efficient and useful source for SSc treatment. Methods We analyzed the content of MSC-conditioned media (MSC-CM) obtained from MSCs isolated from adipose tissue (AT), bone marrow (BM), Wharton's jelly (WJ), and cord blood (CB) by ELISA method, and their effects on the wound healing process by fibroblast proliferation, migration, and ECM deposition assays, to compare regenerative potential of different MSC populations. Results WJ-MSC-conditioned medium (CM) and BM-MSC-CM show a greater regenerative profile, compared to CB-MSC-CM and AT-MSC-CM, due to the abundance of growth factors and immunomodulatory cytokines and t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research